<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530243</url>
  </required_header>
  <id_info>
    <org_study_id>UUNRC 01</org_study_id>
    <nct_id>NCT01530243</nct_id>
  </id_info>
  <brief_title>The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms</brief_title>
  <official_title>Phase One of Study on Urinary Stent Complications and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urmia University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urmia University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigators study is to evaluate whether alpha-blockers such as terazosin
      and anti-cholinergics such as tolterodine can be relieve the DJ-stent related symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ureteral stent (US) has been as essential tool in the urologist's surgeries and is useful
      instruments that its indications increase due to new stent technologies and improvement of
      patient's comfort.

      US associated with discomfort complications that include lower urinary tract symptoms (LUTS)
      as frequency, urgency, dysuria, incomplete emptying, flanks and suprapubic's pain,
      incontinence, hematuria, movement of stent, infection and encrustation of stent. US related
      symptoms are as same as LUTS due to benign prostate hyperplasia and overactive bladder which
      relieve with alpha-blockers and anticholinergic. The purpose of our study is to investigate
      the effect of terazosin and tolterodine lonely and together in comparison of placebo on US
      related symptoms.

      The investigators study will be done prospectively. The patients who underwent indwelling
      Double-j stent distributed into four groups: 1)receive placebo 2)receive terazosin 2mg twice
      3)receive tolterodine 2mg daily 4) receive terazosin 2mg twice and tolterodine 2mg daily. All
      of the patients receive prophylactic antibiotic and on demand analgesic. After entrance to
      study, they fulfill the International Prostatic Symptoms Score (IPSS) and Visual Analog Scale
      (VAS) on the before indwelling US, two weeks after indwelling US and US removal time, then
      the investigators will evaluate the drug's effect on US related symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>Expected average of 2 weeks</time_frame>
    <description>LUTS was evaluated using the International Prostate Symptom Score (IPSS) questionnaire perioperatively. The IPSS constitutes of seven questions assigned score from 0 to 5 to evaluate the severity of LUTS in patients. Total scoring of IPSS ranges from 0 to 35, asymptomatic to very symptomatic. The more the score on scale is, the worse the outcome is.Therefore, the higher values represent worse outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Expected 2 weeks later</time_frame>
    <description>The Quality of life of patients was evaluated using single question in IPSS questionnaire in which each of patients received scoring from 0 to 6. The higher values represent the worse quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain</measure>
    <time_frame>Expected 2 weeks later</time_frame>
    <description>The visual analogue scale (VAS) was used to evaluate the pain at the time of voiding. This VAS scoring ranges from 0 to 10. The higher values represent worse outcomes, having more pain.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Disorder of Urinary Stent</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Terazosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine + Terazosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>same as tolterodine and terazosin dose</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terazosine</intervention_name>
    <description>2 mg BID</description>
    <arm_group_label>Terazosin</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <description>2 mg daily</description>
    <arm_group_label>Tolterodine</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine + Terazosin</intervention_name>
    <description>2mg daily and 2mg BID</description>
    <arm_group_label>Tolterodine + Terazosin</arm_group_label>
    <other_name>Group 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        If a patient does not meet any exclusion criteria and to be undergone double-J stent
        indwelling.

        Exclusion Criteria:

          1. Prior history of pelvic surgery

          2. Prior history of Transurethral Resection of the either Prostate or Bladder Tumor

          3. Benign prostate hyperplasia

          4. Recent or recurrent urinary tract infection

          5. Chronic medication with beta-blockers or Anti-cholinergic

          6. Pregnancy

          7. Prostatitis

          8. Prostate cancer

          9. Bilateral ureteroscopy or ureteral stenting

         10. Age &lt; 18 and &gt; 55

         11. Stone size &gt; 20 mm

         12. Diabetes

         13. Bladder Outlet Obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Tehranchi, Urologist</last_name>
    <role>Study Chair</role>
    <affiliation>Urology department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yousef Rezaei, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urmia University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imam Khomeini Hospital</name>
      <address>
        <city>Urmia</city>
        <state>Azerbaijan-gharbi</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M. Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2013 Nov-Dec;39(6):832-40. doi: 10.1590/S1677-5538.IBJU.2013.06.09.</citation>
    <PMID>24456787</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <results_first_submitted>January 21, 2015</results_first_submitted>
  <results_first_submitted_qc>February 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2015</results_first_posted>
  <last_update_submitted>February 15, 2015</last_update_submitted>
  <last_update_submitted_qc>February 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Terazosin</mesh_term>
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: same as tolterodine and terazosin dose</description>
        </group>
        <group group_id="P2">
          <title>Terazosin</title>
          <description>Terazosin: 2 mg BID</description>
        </group>
        <group group_id="P3">
          <title>Tolterodine</title>
          <description>Tolterodine: 2 mg daily</description>
        </group>
        <group group_id="P4">
          <title>Tolterodine + Terazosin</title>
          <description>Tolterodine + Terazosin: 2mg daily and 2mg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: same as tolterodine and terazosin dose</description>
        </group>
        <group group_id="B2">
          <title>Terazosin</title>
          <description>Terazosine: 2 mg BID</description>
        </group>
        <group group_id="B3">
          <title>Tolterodine</title>
          <description>Tolterodine: 2 mg daily</description>
        </group>
        <group group_id="B4">
          <title>Tolterodine + Terazosin</title>
          <description>Tolterodine + Terazosin: 2mg daily and 2mg BID</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.37" spread="9.58"/>
                    <measurement group_id="B2" value="38.35" spread="9.23"/>
                    <measurement group_id="B3" value="37.04" spread="9.04"/>
                    <measurement group_id="B4" value="35.75" spread="9.38"/>
                    <measurement group_id="B5" value="36.53" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lower Urinary Tract Symptoms (LUTS)</title>
        <description>LUTS was evaluated using the International Prostate Symptom Score (IPSS) questionnaire perioperatively. The IPSS constitutes of seven questions assigned score from 0 to 5 to evaluate the severity of LUTS in patients. Total scoring of IPSS ranges from 0 to 35, asymptomatic to very symptomatic. The more the score on scale is, the worse the outcome is.Therefore, the higher values represent worse outcomes.</description>
        <time_frame>Expected average of 2 weeks</time_frame>
        <population>The more the score on scale is, the worse the outcome is.Therefore, the higher values represent worse outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: same as tolterodine and terazosin dose</description>
          </group>
          <group group_id="O2">
            <title>Terazosin</title>
            <description>Terazosine: 2 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Tolterodine</title>
            <description>Tolterodine: 2 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Tolterodine + Terazosin</title>
            <description>Tolterodine + Terazosin: 2mg daily and 2mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Lower Urinary Tract Symptoms (LUTS)</title>
          <description>LUTS was evaluated using the International Prostate Symptom Score (IPSS) questionnaire perioperatively. The IPSS constitutes of seven questions assigned score from 0 to 5 to evaluate the severity of LUTS in patients. Total scoring of IPSS ranges from 0 to 35, asymptomatic to very symptomatic. The more the score on scale is, the worse the outcome is.Therefore, the higher values represent worse outcomes.</description>
          <population>The more the score on scale is, the worse the outcome is.Therefore, the higher values represent worse outcomes.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.12" spread="7.84"/>
                    <measurement group_id="O2" value="4.39" spread="6.03"/>
                    <measurement group_id="O3" value="7.21" spread="6.57"/>
                    <measurement group_id="O4" value="5.58" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>The Quality of life of patients was evaluated using single question in IPSS questionnaire in which each of patients received scoring from 0 to 6. The higher values represent the worse quality of life.</description>
        <time_frame>Expected 2 weeks later</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: same as tolterodine and terazosin dose</description>
          </group>
          <group group_id="O2">
            <title>Terazosin</title>
            <description>Terazosine: 2 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Tolterodine</title>
            <description>Tolterodine: 2 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Tolterodine + Terazosin</title>
            <description>Tolterodine + Terazosin: 2mg daily and 2mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>The Quality of life of patients was evaluated using single question in IPSS questionnaire in which each of patients received scoring from 0 to 6. The higher values represent the worse quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="2.16"/>
                    <measurement group_id="O2" value="2" spread="2.25"/>
                    <measurement group_id="O3" value="2.30" spread="1.89"/>
                    <measurement group_id="O4" value="0.95" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pain</title>
        <description>The visual analogue scale (VAS) was used to evaluate the pain at the time of voiding. This VAS scoring ranges from 0 to 10. The higher values represent worse outcomes, having more pain.</description>
        <time_frame>Expected 2 weeks later</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: same as tolterodine and terazosin dose</description>
          </group>
          <group group_id="O2">
            <title>Terazosin</title>
            <description>Terazosin: 2 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Tolterodine</title>
            <description>Tolterodine: 2 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Tolterodine + Terazosin</title>
            <description>Tolterodine + Terazosin: 2mg daily and 2mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>The visual analogue scale (VAS) was used to evaluate the pain at the time of voiding. This VAS scoring ranges from 0 to 10. The higher values represent worse outcomes, having more pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="3.59"/>
                    <measurement group_id="O2" value="3.21" spread="4.14"/>
                    <measurement group_id="O3" value="1.34" spread="2.60"/>
                    <measurement group_id="O4" value="1.37" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: same as tolterodine and terazosin dose</description>
        </group>
        <group group_id="E2">
          <title>Terazosin</title>
          <description>Terazosin: 2 mg BID</description>
        </group>
        <group group_id="E3">
          <title>Tolterodine</title>
          <description>Tolterodine: 2 mg daily</description>
        </group>
        <group group_id="E4">
          <title>Tolterodine + Terazosin</title>
          <description>Tolterodine + Terazosin: 2mg daily and 2mg BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Applying stents with the same size and length</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Yousef Rezaei</name_or_title>
      <organization>Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences</organization>
      <phone>+989126231864</phone>
      <email>yousefrezaei1986@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

